Pricing Log in Create free account
Sunday 8 November 2026 Export OGN’s income statement to Excel — free account

Organon & Co.

OGN

Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.

Revenue
−1.75%
EPS
+1.64%
Free cash flow
+118.8%
Total debt
−3.10%

Quarter to September 2026, against a year earlier

13.87 0.08 +0.58%
Market cap
$3.6B
P/E
17.3×
Fwd P/E
6.2×
Dividend yield
0.58%
F-score
5/9
ROIC
6.26%
Net debt / EBITDA
5.6×
Dividend safety
45/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Net sold
$553.4K
Trades
2 sells · 0 buys
Ownership
0.64%

Capital & Financial Ratios $m

Size
Market Cap 3,620
Revenue ttm 6,099
Net income ttm 213
Free cash flow ttm 572
Net debt Q 7,099
Valuation
P/E 17.3
Forward P/E 6.2
Price / sales 0.6
Forward P/S Powerpack
Price / FCF 6.3
Price / book 3.0
Financial health
Current ratio Q 2.0 (at or above 1.5: strong)
Debt / equity Q 7.2 (above 2: weak)
Interest coverage Q 3.4
Growth
Revenue growth Q −1.7% (below 0%: shrinking)
Operating income growth Q +2.0% (above 0%: growing)
EPS, this year −8.5% (below 0%: weak)
EPS, next year A +8.4%
Revenue, next year A −0.9% (below 0%: weak)
EPS, past 5 yrs −39.0% (below 0%: weak)
EPS, next 5 yrs A +3.1%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.8×, against a ten-year median of 2.0×; over the ten years it ranged from 1.5× in 2026 to 2.8× in 2022.
P/E against its own 10 years 97.61%
10-year low 10-year high
P/S against its own 10 years 33.31%
10-year low 10-year high
EV/Sales against its own 10 years 21.92%
10-year low 10-year high
EV/FCF against its own 10 years 41.36%
10-year low 10-year high

Dividends

Yield
0.58%
Annual rate
0.08
Payout ratio
10.5%
Growth, 2021–26
−32.2%/yr
  1. 0.56 ’21
  2. 1.12 ’22 +100
  3. 1.12 ’23 +0
  4. 1.12 ’24 +0
  5. 0.34 ’25 −70
  6. 0.08 ’26 −76
paid change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 693 675 574 1,455
Receivables 1,744 1,358 1,331 1,480
Inventory 1,315 1,321 1,406 1,355
Other 756 994 1,041 1,079
4,508 4,348 4,352 5,369
2023 2024 2025 Q'26
Payables 1,314 1,153 952 982
ST’ Debt 9 20 16 69
Other — — 2 —
2,918 2,718 2,390 2,652

Compound Annual Growth %

10y 5y 3y
Sales — (0.99%) 0.23%
Cash Flow — (21.06%) (6.56%)
Earnings — (38.70%) (41.14%)
Book Value — (32.80%) 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.91 Actual 0.94

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.73 0.63 Miss by 0.10
Q1 FY26 0.83 0.71 Miss by 0.12
Q2 FY26 0.87 0.85 Miss by 0.02
Q3 FY26 0.91 0.94 Beat by 0.03
Q4 FY26 0.83 — Reports 11 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.55 0.40 0.60 — —
’25 0.33 0.56 0.61 (0.79) 0.72
’24 0.78 0.75 1.38 0.42 3.33
’23 0.69 0.95 0.23 2.13 3.99
’22 1.36 0.92 0.89 0.42 3.59
’21 1.58 1.68 1.27 0.79 5.31
’20 2.77 2.14 2.16 1.45 8.52
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 1,460 1,558 1,574 — —
’25 1,513 1,594 1,602 1,507 6,216
’24 1,622 1,607 1,582 1,592 6,403
’23 1,538 1,608 1,519 1,598 6,263
’22 1,567 1,585 1,537 1,485 6,174
’21 1,506 1,595 1,600 1,603 6,304
’20 1,780 1,526 1,613 1,613 6,532
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 225 107 370 — —
’25 75 220 264 141 700
’24 76 332 141 390 939
’23 114 27 261 397 799
’22 123 151 317 267 858
’21 1,300 445 368 47 2,160
’20 747 733 320 387 2,284
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 188 31 326 — —
’25 (12) 182 149 96 415
’24 (20) 301 77 305 663
’23 68 (43) 206 316 547
’22 60 68 209 208 545
’21 1,262 388 140 (7) 1,783
’20 708 686 275 260 2,034
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 10,500 9,777 7,777 6,532 6,304 6,174 6,263 6,403 6,216 6,099 (6.3%) 6,158 6,285 6,435 +1.2%
Gross margin, % — 56.30 52.00 70.76 67.56 62.21 62.84 59.84 58.02 53.30 53.12 (3.0) pt
EBT — 3,099 2,729 3,696 2,752 1,529 1,122 673 807 425 503 (22.0%)
EBT margin, % — 29.51 27.91 47.52 42.13 24.25 18.17 10.75 12.60 6.84 8.25 (22.7) pt
Net income — 0 2,153 3,306 2,256 0 917 1,023 864 187 213 n/m
Per share, $
Per share, $ Revenue — 41.50 38.64 30.68 25.77 24.86 24.30 24.54 24.91 23.95 23.22 (6.6%)
Earnings — 7.11 8.51 12.69 8.52 5.33 3.61 4.01 3.36 0.72 0.80 (24.9%)
Cash flow — 13.51 14.57 11.91 9.01 8.52 3.38 3.13 3.65 2.70 3.21 (18.2%)
Capex — 0.00 (0.27) (0.35) (0.99) (1.49) (1.23) (0.99) (1.07) (1.10) (1.03) n/m
Free cash flow — 13.51 14.30 11.57 8.02 7.03 2.15 2.14 2.58 1.60 2.18 (23.4%)
Book value — 0.00 0.00 27.75 21.64 (5.95) (3.51) (0.27) 1.84 2.90 4.54 n/m
Shares, m — 253 253 254 254 254 254 255 257 259 261 +0.3%
Valuation, ×
Valuation, × P/E — 4.54 4.54 4.54 4.54 5.71 7.80 3.66 4.45 9.96 17.29 5.5
P/S — 1.35 1.35 1.35 1.35 1.22 1.16 0.60 0.60 0.30 0.60 1.0
P/B — 1.79 1.79 1.79 1.79 0.00 0.00 0.00 8.13 2.47 3.04 2.0
EV/Sales — 1.49 1.49 1.49 1.49 2.56 2.48 1.89 1.88 1.60 1.76 1.8
EV/FCF — 3.76 3.76 3.76 3.76 8.16 28.15 26.10 18.16 23.93 18.76 13.3
Cash, $m
Cash, $m Operating cash flow — 3,419 3,687 3,020 2,284 2,160 858 799 939 700 843 (18.0%)
Capex — (86) (69) (88) (250) (377) (313) (252) (276) (285) (271) +16.2%
Free cash flow — 3,419 3,618 2,932 2,034 1,783 545 547 663 415 572 (23.2%)
Balance, $m
Balance, $m Working capital — — 2,169 2,614 894 1,163 1,419 1,590 1,630 1,962 2,717 (1.4%)
Net debt — — (95) (201) 19 8,397 8,207 8,067 8,205 8,070 7,099 n/m
Shareholders’ equity — — — 7,035 5,486 (1,508) (892) (70) 472 752 1,193 (31.1%)
Returns, %
Returns, % ROA — 0.00 0.00 61.02 20.91 13.00 8.48 8.89 6.87 1.44 1.58 +1.4 pt
ROIC — — 0.00 33.80 31.74 16.25 13.41 9.82 9.90 5.84 6.26 +5.8 pt
ROE — 0.00 32.18 48.09 34.50 67.92 (76.42) (212.68) 429.85 30.56 20.30 +30.6 pt
People
People Employees — — — — 9,950 9,300 10,000 10,000 4,000 10,000 — +0.1%
Revenue/emp, $m — 0.00 0.00 0.00 0.66 0.68 0.62 0.63 1.60 0.62 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Organon & Co. vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PFE Pfizer Inc. $170.3B 41.3× 17.7× −0.43% (below 0%: shrinking) −7.98% (below 0%: shrinking) +20.02% (above 0%: growing) 75.71% 22.14% Compare
NVO Novo Nordisk A/S $134.8B 10.1× — +3.87% (above 0%: growing) −16.40% (below 0%: shrinking) +71.57% (above 0%: growing) 76.97% 29.06% Compare
BMY Bristol Myers Squibb Company $129.0B 13.7× 11.8× +6.93% (above 0%: growing) −2.02% (below 0%: shrinking) −35.95% (below 0%: shrinking) 68.28% 19.40% Compare
SNY Sanofi $111.8B 23.3× — +13.89% (above 0%: growing) +8.21% (above 0%: growing) +99.60% (above 0%: growing) 76.16% 28.53% Compare
GSK GSK PLC Sponsored ADR $101.0B 16.7× 15.3× +3.75% (above 0%: growing) −14.73% (below 0%: shrinking) +62.44% (above 0%: growing) 73.11% 23.93% Compare
BIIB Biogen Inc. $36.1B 105× 46.4× +10.63% (above 0%: growing) n/m −69.25% (below 0%: shrinking) 73.31% 4.58% Compare
OGN Organon & Co. $3.6B 17.3× 6.2× −1.75% (below 0%: shrinking) +1.64% (above 0%: growing) +118.79% (above 0%: growing) 55.21% 23.19%
GRFS Grifols, S.A. $2.2B 18.2× — +9.37% (above 0%: growing) +59.78% (above 0%: growing) +4.11% (above 0%: growing) 39.56% 19.22% Compare
AMRN Amarin Corporation PLC $244.0M — (loss-making) — (loss-making) −20.37% (below 0%: shrinking) n/m +172.64% (above 0%: growing) 40.91% (5.97%) Compare
Median of peers $106.4B 18.2× 16.5× +5.40% −5.00% +41.23% 73.21% 20.77%

All 21 Drug Manufacturers General stocks →

Pay and ownership Proxy statement filed 24 April 2026

Ownership

Directors and executive officers, together 1.62%
BlackRock, Inc. 11.68%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Organon & Co. (OGN) Latest News

26 Oct

Impact 3 · · Zacks

19 Oct

Impact 3 · · Business Wire

16 Oct

Impact 4 · · Business Wire

14 Oct

Impact 3 · · Zacks

2 Oct

Impact 3 · · Zacks

1 Oct

Impact 3 · · Business Wire

28 Sep

Impact 3 · · CNW Group

22 Sep

Impact 4 · · Simply Wall St.

21 Sep

Impact 4 · · Simply Wall St.
Impact 3 ·

14 Sep

Impact 4 ·

10 Sep

Impact 3 ·

8 Sep

Impact 3 · · Zacks

11 Aug

Impact 3 ·

31 Jul

Impact 3 ·

24 Jul

Impact 4 ·

23 Jul

Impact 4 · · MarketBeat

30 Jun

Impact 4 ·

23 Jun

Impact 3 · · Business Wire

22 Jun

Impact 4 · · Business Wire

15 Jun

Impact 4 ·
Impact 3 ·

12 Jun

Impact 4 ·

10 Jun

Impact 4 · · Business Wire

25 May

Impact 3 · · Simply Wall St.

21 May

Impact 3 · · GlobeNewswire

7 May

Impact 5 · · Simply Wall St.

1 May

Impact 4 · · Insider Monkey

30 Apr

Impact 4 · · Zacks
Impact 3 · · StockStory

OGN metrics, ten years each

stockrow.com/OGN · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com